Get the Latest CDMO Stock Quote and Company Insights

To get the latest CDMO stock quote, simply type the ticker symbol into a financial search engine or website, and you'll be presented with the current market price and other relevant data.

CDMO stock quotes can be found on various financial websites, such as Yahoo Finance or Google Finance.

Some CDMOs, like Catalent, have seen significant growth in recent years due to increased demand for contract manufacturing services.

Catalent's stock price has risen by over 50% in the past year, making it a popular choice for investors looking to diversify their portfolios.

CDMO stock quote is a publicly traded company, listed on the NASDAQ stock exchange.

CDMO's headquarters is located in the United States.

CDMO's primary business is contract development and manufacturing, serving the pharmaceutical and biotechnology industries.

CDMO has a significant presence globally, with operations in multiple countries.

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture.

The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Avid Bioservices offers a range of services, including process development and CGMP clinical and commercial manufacturing, catering to the needs of the biotechnology and biopharmaceutical industries.

The company is headquartered in a location that is not specified in the article.

Avid Bioservices is a clinical-stage biopharmaceutical company with a focus on mammalian cell culture-derived biopharmaceutical products.

Avid Bioservices is urging its stockholders to vote in favor of its pending transaction with GHO Capital Partners and Ampersand Capital Partners.

The Special Meeting to vote on the transaction is scheduled for January 30, 2025.

Avid's Board unanimously recommends stockholders vote 'FOR' the transaction, highlighting three key benefits: immediate cash value, a robust value-maximizing process, and de-risking of the company's standalone future.

The deal offers a 13.8% premium to Avid's last trading price before announcement and a 6.3x multiple to consensus FY2025E revenue.

The transaction equates to $12.50 per share in cash, representing a $1.1 billion enterprise value.

Stockholders of record as of December 11, 2024, are eligible to vote.

The Board has filed an investor presentation highlighting the value-maximizing transaction with GHO and Ampersand.

The deal resulted from a robust process where the Board rejected two initial proposals before conducting a broader search involving 24 potential parties.

The company's five-year growth prospects were noted to be below previous guidance and analyst consensus.

Avid's president and CEO, Nick Green, emphasized that the transaction will deliver significant, immediate, and certain value to stockholders.

The transaction is expected to close in the first quarter of 2025, subject to stockholder and regulatory approvals.

The current share price of Avid Bioservices is $12.43, which is a 1.55% increase from last month. This is a relatively small change compared to the 22.46% increase seen over the past three months.

Over the past year, the share price has skyrocketed by 79.88%, but it's worth noting that the 3-year change has been a decline of 34.48%. This indicates a significant fluctuation in the company's stock performance.

Here's a breakdown of the 52-week high and low prices: $12.48 and $5.90, respectively. The beta of 1.41 suggests that the company's stock price is more volatile than the overall market.

The price history of Avid Bioservices, or CDMO, is quite impressive. Over the past year, the company's share price has increased by a whopping 79.88%.

In terms of its 52-week high and low, CDMO's share price has reached as high as $12.48 and as low as $5.90. This volatility might be a concern for some investors. However, if you look at the bigger picture, the company's beta, which measures its volatility relative to the market, is 1.41.

CDMO's share price has also shown significant growth over the past three months, with a 22.46% increase. This is a much faster rate of growth than the US market as a whole, which has seen a 1.55% increase over the same period.

Here's a summary of CDMO's price history and performance:

The GF Value Rank is a crucial metric to assess a company's financial performance. It's calculated based on various valuation multiples, such as the Price-to-Book (PB) Ratio, which stands at 17.76.

The PB Ratio is a widely used metric to evaluate a company's stock price relative to its book value. In this case, the PB Ratio is significantly higher than the industry average, indicating that the company's stock price is relatively high compared to its book value.

The GF Value Rank also considers other valuation multiples, such as the Price-to-Operating-Cash-Flow (P/OCF) Ratio, which is 149.76. This suggests that the company's stock price is extremely high relative to its operating cash flow.

Here's a summary of the GF Value Rank metrics:

The GF Value Rank also includes the Earnings Yield (Greenblatt) %, which is -2.77%. This indicates that the company's earnings yield is extremely low, suggesting that the company's stock price is relatively high compared to its earnings.

In conclusion, the GF Value Rank is a comprehensive metric that provides valuable insights into a company's financial performance. By analyzing various valuation multiples, we can gain a deeper understanding of a company's stock price and its underlying value.